CGL
AZN icon

Clarius Group LLC’s AstraZeneca AZN Stock Holding History

Clarius Group LLC’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$981K Hold
5,336
– – 0.06% 127
2025
Q3 		$819K Sell
5,336
-1,391
-21% -$211K 0.05% 150
2025
Q2 		$940K Sell
6,727
-193
-3% -$27K 0.05% 154
2025
Q1 		$1.02M Buy
6,920
+1,649
+31% +$239K 0.06% 139
2024
Q4 		$691K Buy
5,271
+167
+3% +$23.4K 0.05% 168
2024
Q3 		$795K Sell
5,104
-1,481
-22% -$239K 0.06% 145
2024
Q2 		$1.03M Sell
6,585
-1,243
-16% -$187K 0.07% 113
2024
Q1 		$1.06M Sell
7,828
-616
-7% -$81.6K 0.07% 111
2023
Q4 		$1.14M Sell
8,444
-210
-2% -$27.3K 0.09% 110
2023
Q3 		$1.17M Sell
8,654
-759
-8% -$104K 0.11% 100
2023
Q2 		$1.35M Buy
9,413
+4
+0% +$589 0.1% 103
2023
Q1 		$1.31M Buy
9,409
+163
+2% +$21.9K 0.11% 106
2022
Q4 		$1.25M Buy
9,246
+923
+11% +$116K 0.11% 111
2022
Q3 		$913K Buy
8,323
+507
+6% +$64.3K 0.09% 131
2022
Q2 		$1.03M Sell
7,816
-59
-0.7% -$7.74K 0.1% 122
2022
Q1 		$917K Hold
7,875
– – 0.07% 150
2021
Q4 		$917K Buy
7,875
+3,365
+75% +$396K 0.07% 150
2021
Q3 		$542K Buy
4,510
+1,452
+47% +$169K 0.05% 200
2021
Q2 		$366K Buy
3,058
+193
+7% +$21.2K 0.03% 272
2021
Q1 		$285K Sell
2,865
-1,398
-33% -$141K 0.03% 297
2020
Q4 		$426K Buy
4,263
+1,216
+40% +$129K 0.05% 195
2020
Q3 		$334K Sell
3,047
-33
-1% -$3.67K 0.04% 198
2020
Q2 		$326K Buy
3,080
+5
+0.2% +$516 0.05% 201
2020
Q1 		$275K Sell
3,075
-23
-0.7% -$2.17K 0.05% 190
2019
Q4 		$315K Buy
3,098
+29
+0.9% +$2.73K 0.05% 197
2019
Q3 		$274K Buy
+3,069
New +$266K 0.05% 206
2018
Q4 		– Sell
-3,032
Closed -$240K – 120
2018
Q3 		$240K Hold
3,032
– – 0.09% 106
2018
Q2 		$213K Buy
+3,032
New +$218K 0.09% 81

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clarius Group LLC's AZN Position: Q4 2025 in Review

Clarius Group LLC held its AstraZeneca (AZN) position steady in Q4 2025 at 5,336 shares worth $981K. The position accounts for 0.06% of the portfolio, ranked #127.

Clarius Group LLC first reported a position in AZN in Q2 2018 and has held it in 28 quarters since. The position peaked at $1.35M in Q2 2023. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Clarius Group LLC held 5,336 shares of AstraZeneca worth $981K as of Q4 2025.
  • Clarius Group LLC left its AstraZeneca share count unchanged in Q4 2025.
  • AstraZeneca made up 0.06% of Clarius Group LLC's portfolio in Q4 2025, its #127 holding.
  • Clarius Group LLC first reported a position in AstraZeneca in Q2 2018 and has held it in 28 quarters since.
  • Clarius Group LLC's AstraZeneca position peaked at $1.35M in Q2 2023.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.